pha-793887
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00996255)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclin-dependent kinaseINHIBITOR
Cyclin-dependent kinase inhibitor
- Cyclin-dependent kinase 1 (CDK1) ↗
- Cyclin-dependent kinase 4 (CDK4) ↗
- Cyclin-dependent kinase 2 (CDK2) ↗
- Cyclin-dependent-like kinase 5 (CDK5) ↗
- Cyclin-dependent kinase 6 (CDK6) ↗
- Cyclin-dependent kinase 7 (CDK7) ↗
- Cyclin-dependent kinase 3 (CDK3) ↗
- Cyclin-dependent kinase 16 (CDK16) ↗
- Cyclin-dependent kinase 18 (CDK18) ↗
- Cyclin-dependent kinase 8 (CDK8) ↗
- Cyclin-dependent kinase 17 (CDK17) ↗
- Cyclin-dependent kinase 11B (CDK11B) ↗
- Cyclin-dependent kinase 15 (CDK15) ↗
- Cyclin-dependent kinase 19 (CDK19) ↗
- Cyclin-dependent kinase 14 (CDK14) ↗
- Cyclin-dependent kinase 9 (CDK9) ↗
- Cyclin-dependent kinase 10 (CDK10) ↗
- Cyclin-dependent kinase 13 (CDK13) ↗
- Cyclin-dependent kinase 20 (CDK20) ↗
- Cyclin-dependent kinase 12 (CDK12) ↗
- Cyclin-dependent kinase 6
- Cyclin-dependent kinase 9
- Cyclin-dependent kinase 2
- Cyclin-dependent kinase 1
- Cyclin-dependent kinase 3
- Cyclin-dependent kinase 7
- Cyclin-dependent kinase 4
- Cyclin-dependent kinase 5
- Serine/threonine-protein kinase PCTAIRE-1
- Serine/threonine-protein kinase PCTAIRE-3
- Cell division protein kinase 8
- PITSLRE serine/threonine-protein kinase CDC2L1
- Serine/threonine-protein kinase PFTAIRE-2
- Cell division cycle 2-like protein kinase 6
- Serine/threonine-protein kinase PFTAIRE-1
- Serine/threonine-protein kinase PCTAIRE-2
- Cyclin-dependent kinase 10
- Cyclin-dependent kinase 13
- Cyclin-dependent kinase 2 and 4 (CDK2 and CDK4)
- CDK2/CDK4
- Cyclin-dependent kinase 20
- Cyclin-dependent kinase 12
- Cyclin-dependent kinase 4/6
- Cyclin-dependent kinase 8/19
- CDK4/CDK9
- Cyclin-dependent kinase 12/13
- CDK4/CDK1
- Cyclin-dependent kinase 2/4/6
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C- Mol. weight
- 361.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1230607 ↗
Also known as
- n-(6,6-dimethyl-5-((1-methylpiperidin-4-yl)carbonyl)-1,4,5,6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-methylbutanamide
- pha793887
- pha 793887
- pha-793887
- pha-793887
- pha-793887
- pha-793887
- pha-793887
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00996255 | Phase 1 | Nov 1, 2006 | Institut Gustave Roussy, Nerviano Medical Sciences, University of Leeds |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Nerviano Medical Sciences | For profit | 1 | 1 | 1 | 2006 |
| University of Leeds | Academic/Hospital | 1 | 0 | 1 | 2006 |
3 organizations
Page 1 / 1